Idelalisib (CAL-101, GS-1101)

製品コードS2226

Idelalisib (CAL-101, GS-1101)化学構造

分子量(MW):415.42

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

サイズ 価格(税別)  
JPY 25896.00
JPY 19920.00
JPY 78020.00

文献中の使用例(30)

カスタマーフィードバック(4)

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
ターゲット
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外試験

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WzRWROW09? NVrQWHZHUUN3ME2yNE41KM7:TR?= M1;0T|I2QTl7M{Wy
CLL PBMCs Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXJSG1UVw>? MVjJR|UxRTJwOTDuUS=> M2LvXlI2QTF5Mk[3
U266 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfhVmIyPDBizszN MVu0PEBp MYK3PU42LSCrbnjpZol1cW:wIILheIU> MljnNlU{Ozl|M{K=
K562 Mki5SpVv[3Srb36gRZN{[Xl? NXTDWlI1OSEQvF2= MUCzJIg> MYnJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NX;vc4wzOjVyMUS3O|U>
K562 MWDGeY5kfGmxbjDBd5NigQ>? NEK0VlUyKM7:TR?= NHfMW2s{KGh? NIPOeZNKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> M3rRVlI2ODF2N{e1
K562 MkfRSpVv[3Srb36gRZN{[Xl? MmDLNUDPxE1? MWezJIg> M1LyOmlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= MUiyOVAyPDd5NR?=
K562 M3vLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULtSWNvOSEQvF2= NEGwXmE4OiCq MonpTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u MU[yOVAyPDd5NR?=
Primary AML cell NH\lU4VHfW6ldHnvckBCe3OjeR?= M3XFe|Eh|ryP NV:3dlcxOyCq MV\Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NVnKVXd3OjVyMUS3O|U>
Primary AML cell M2HCS2Z2dmO2aX;uJGF{e2G7 NWHwUXBrOSEQvF2= NVfSUG9pOyCq NVnYepNWUW6qaXLpeIlwdiCxZjDQO|BUPkticHjvd5Bpd3K7bHH0bY9v MnPtNlUxOTR5N{W=
Primary AML cell NX;wd5RoTnWwY4Tpc44hSXO|YYm= NIXMVXAyKM7:TR?= NHvLenQ{KGh? Mkf2TY5pcWKrdHnvckBw\iCJU1uzJJBpd3OyaH;yfYxifGmxbh?= Mlz4NlUxOTR5N{W=
Primary AML cell MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjZlEh|ryP MmDFN{Bp NVTsdGV1W3WycILld5Nqd25ib3[gdnJPSSC|eX70bIV{cXN? NFzjeVEzPTBzNEe3OS=>
Microglia NUPkPYZFTnWwY4Tpc44hSXO|YYm= NGjFOY42KM7:TR?= MoK1NVAhcA>? NGPid4xFVVOR NWX1bVBJTGWlcnXhd4Uhd2ZiVF7GZUB{\WO{ZYTpc44h\nKxbTDMVHMue3SrbYXsZZRm\CBicEGxNO61TDlzMFGvSFkyOEFibXnjdo9odGmj NHvsV2kzPDZ{NU[4OC=>
Primary CLL cell NVSwRW1OTnWwY4Tpc44hSXO|YYm= NHi2OHMyKM7:TR?= M1\3VlE2KG2rbh?= MlTRSG1UVw>? NFzCcIFDdG:la4OgRmNTNWmwZIXj[YQhVEOSMTDz[ZJqdmVvNTDhZ5RqfmG2aX;u MkfVNlQxODl{M{O=
JEKO-1 MVPGeY5kfGmxbjDBd5NigQ>? M2nod|Eh|ryP MVm3NkBp NIPEZY9KdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gbY4hUWePLYP0bY12dGG2ZXSgTmVMVy1z NG\zb4ozOzN2MUW0NS=>
Granta-519 M4H5RmZ2dmO2aX;uJGF{e2G7 NX30coZjOSEQvF2= M{\OZVIhcA>? MmiwTY5pcWKrdHnvckBw\iCDa4SoeFMxQClicHjvd5Bpd3K7bHH0bY9v NXTRZnZEOjN|NEG1OFE>
Granta-519 NULDVlB6TnWwY4Tpc44hSXO|YYm= NYLL[5hXOSEQvF2= NXjOV5hDOiCq MmLqTY5pcWKrdHnvckBw\iCDa4Sod|Q4OylicHjvd5Bpd3K7bHH0bY9v MmjsNlM{PDF3NEG=
JEKO-1 NGPHRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1SYtiOTBizszN M4S5[VczKGh? MlvGTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJJNtcWeqdHz5 MV6yN|M1OTV2MR?=
JEKO-1 NFXnU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXROUDPxE1? NXzO[oNHPzJiaB?= NGTxZ2hld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ MUmyN|Y4PjJ{MB?=
MAVER-1 NYW0dZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfLOUDPxE1? MlO0O|IhcA>? MkLB[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=> MYqyN|Y4PjJ{MB?=
MINO MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTjb|lYPSEQvF2= MVm3NkBp M3jEdoRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> NVPvbWVyOjN4N{[yNlA>
SP53 M3LDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PyUVAvOSEQvF2= Mnm5O|IhcA>? MVTkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz MlzyNlM3PzZ{MkC=
HH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNEDPxE1? NYnCb|ZVPzJiaB?= M3HQW2ROW09? MmLiTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NVX5S|FwOjJ6MEG5OVk>
Myla Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWixNEDPxE1? NWP4[pR5PzJiaB?= M13iUGROW09? MWTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| M3T5dlIzQDBzOUW5
SR786 M17XVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4NVAh|ryP NVT2XpFLPzJiaB?= NVe0R|dRTE2VTx?= Mkjp[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NHiyWmIzOjhyMUm1PS=>
HuT78 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjFfmYyOCEQvF2= NVqzcpVGPzJiaB?= MojnSG1UVw>? M1fxeYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NX7VW3VwOjJ6MEG5OVk>
MJ NVLFfGVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxNEDPxE1? NF20PJg4OiCq NUPRTWNrTE2VTx?= M2\KPIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NWTkVY1FOjJ6MEG5OVk>
DERL7 NWnHRnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDMRZMyOCEQvF2= MWG3NkBp NVLERoVxTE2VTx?= NFjTU45ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NYnwempMOjJ6MEG5OVk>
L1236 Ml6xSpVv[3Srb36gRZN{[Xl? MX2xNEDPxE1? NYC4eXJiOiCq M1OxN2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= NWjtUZNGOjJ{MUC4O|c>
L428 M37vZ2Z2dmO2aX;uJGF{e2G7 NV7ZVJIxOTBizszN M4T4OFIhcA>? MkHLTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w MmfSNlIzOTB6N{e=
L591 NH2wbGJHfW6ldHnvckBCe3OjeR?= MnHvNVAh|ryP MX2yJIg> Mn[1TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w M3HRUFIzOjFyOEe3
KMH-2 M{\hVmZ2dmO2aX;uJGF{e2G7 NI\TPGoyOCEQvF2= NFPzNXYzKGh? M{\IV2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= NYfucXU6OjJ{MUC4O|c>
L1236 MlHmSpVv[3Srb36gRZN{[Xl? NGfvfZU2KM7:TR?= MVqyOEBp MUTCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 MnX4NlIzOTB6N{e=
L591 MV3GeY5kfGmxbjDBd5NigQ>? Mne4OUDPxE1? NIrTOVEzPCCq MW\CcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 NXm1e2lvOjJ{MUC4O|c>
L1236 MVnBdI9xfG:|aYOgRZN{[Xl? NF3Wd482KM7:TR?= MWSyOEBp NVf4PGp{UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MmCxNlIzOTB6N{e=
L591 MlK1RZBweHSxc3nzJGF{e2G7 M{OwWlUh|ryP MknzNlQhcA>? NHfId2JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| NVXQOFFQOjJ{MUC4O|c>
U-87MG Mlv6SpVv[3Srb36gRZN{[Xl? MnnFNVAxKG6P NGfTSVYzPCCq NY\mNGZqTE2VTx?= M3jINmlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v Ml;RNlIxPzl4MEm=
SW1783 NWnR[WxpTnWwY4Tpc44hSXO|YYm= NYDVWFVEOTByIH7N NFH2bIUzPCCq MXzEUXNQ MlHOTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> NVnZfYp6OjJyN{m2NFk>
U-87MG NUjwOmNHTnWwY4Tpc44hSXO|YYm= NXPDUndQPSEQvF2= MUKyOEBp M2\JcmROW09? M1TnS2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6 NV\IclV2OjJyN{m2NFk>
SW1783 NHrWWnZHfW6ldHnvckBCe3OjeR?= M1m1ZlUh|ryP NXXRVlVzOjRiaB?= MXnEUXNQ MlixTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> NXnnS2xPOjJyN{m2NFk>
U-373MG M3qweGZ2dmO2aX;uJGF{e2G7 MWm1JO69VQ>? MUCyOEBp NFXI[mtFVVOR NGfmU49KdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? MkDvNlIxPzl4MEm=
SK-MG3 NHHsR|hHfW6ldHnvckBCe3OjeR?= NUTCVVB3PSEQvF2= NYizNmp6OjRiaB?= MYnEUXNQ NF7s[HhKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? MoLzNlIxPzl4MEm=
SU-DHL-5 MYjGeY5kfGmxbjDBd5NigQ>? M3O4PVEh|ryP MWCyOEBp MmLzSG1UVw>? MorrTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? NHrtTpAzODl3OU[wOi=>
WSU-NHL M1XNNWZ2dmO2aX;uJGF{e2G7 MWWxJO69VQ>? NXrOVoZvOjRiaB?= M2\KfGROW09? NUfyVHFqUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MorQNlA6PTl4ME[=
CCRF-SB NWLY[XBJTnWwY4Tpc44hSXO|YYm= Ml;nNUDPxE1? Ml\XNlQhcA>? MYXEUXNQ MVTJcoR2[3Srb36gc4Yh[XCxcITvd4l{ MmLDNlA6PTl4ME[=
INA-6 NGq5bFJHfW6ldHnvckBCe3OjeR?= MUe1JO69VQ>? Ml;COkBp NWGzSHc6UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl? NGLsUnMzODVyNUG1PC=>
LB NXLIXVZXTnWwY4Tpc44hSXO|YYm= NGTMVVQ2KM7:TR?= NIPjTm83KGh? MXrJcohq[mm2aX;uJI9nKFCLNFuvRYt1KGGwZDDFVmsheGG2aIfhfS=> M4jBR|IxPTB3MUW4

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

キナーゼ試験:[2]
+ 展開

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
細胞試験: [2]
+ 展開
  • 細胞株: CLL B cells or healthy volunteer T cells or NK cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ: MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 83 mg/mL (199.79 mM) warming
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
混合させたのち直ちに使用することを推奨します。
30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 415.42
化学式

C22H18FN7O

CAS No. 870281-82-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02457598 Recruiting B-cell Malignancies Gilead Sciences June 30, 2015 Phase 1
NCT02962401 Not yet recruiting Waldenstrom Macroglobulinemia French Innovative Leukemia Organisation January 2017 Phase 2
NCT02928510 Not yet recruiting Absence of Signs or Symptoms|B-Cell Non-Hodgkin Lymphoma|Digestive System Signs and Symptoms|Indolent Adult Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma Jonsson Comprehensive Cancer Center|Gilead Sciences|National Cancer Institute (NCI) January 2017 --
NCT02968563 Recruiting Chronic Lymphocytic Leukemia Gilead Sciences|German CLL Study Group December 2016 Phase 2
NCT02639910 Recruiting Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma MorphoSys AG November 2016 Phase 2
NCT02970318 Recruiting Chronic Lymphocytic Leukemia Acerta Pharma BV September 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. http://www.ncbi.nlm.nih.gov.ezproxy.liv.ac.uk/pubmed/?term=PI3K%CE%B4+inhibition+reduces+TNF+secretion+and+neuroinflammation+in+a+mouse+cerebral+stroke+model

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Idelalisib (CAL-101, GS-1101)を買う | Idelalisib (CAL-101, GS-1101) ic50 | Idelalisib (CAL-101, GS-1101)供給者 | Idelalisib (CAL-101, GS-1101)を購入する | Idelalisib (CAL-101, GS-1101)費用 | Idelalisib (CAL-101, GS-1101)生産者 | オーダーIdelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)化学構造 | Idelalisib (CAL-101, GS-1101)分子量 | Idelalisib (CAL-101, GS-1101)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID